Curis, Inc. (NASDAQ:CRIS)
A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
marsuculix
(< 20)
Submitted: 5/23/2013 7:23:25 AM :
Start Price:
$3.58
CRIS Score:
-5.50
ASCO 2013 gives upside potential !
Recs
zzlangerhans
(99.76)
Submitted: 2/20/2013 9:53:03 AM :
Start Price:
$2.90
CRIS Score:
+10.01
Curis has been annoying a lot of knowledgeable biopharma traders for quite a few months as the share price has inexorably declined despite encouraging progress in their pipeline. I have no idea if that trend is about to reverse, so this green thumb is simply a flag for me to keep a careful eye on the stock in case it declines even further. I've taken Curis to the woodshed more than once in the past when they seemed unable to achieve success in any effort more advanced than a phase I trial, but I like that they have achieved their first drug approval (although for a small indication). Outside of Erivedge, the pipeline includes four candidates in early development and there are ongoing relationships with Genentech and Debiopharm. I wouldn't call Curis the next Ariad or Incyte yet but I've seen enough to swing me over the line into cautious optimism.
Recs
RBuskey106
(33.54)
Submitted: 3/14/2012 10:40:32 PM :
Start Price:
$4.54
CRIS Score:
-41.98
Skin cancer drug approved. Working closely with Roche--buyout potential
Recs
portefeuille
(99.75)
Submitted: 12/15/2011 11:00:10 PM :
Start Price:
$3.14
CRIS Score:
-34.99
There are currently 1000 CRIS shares in my "fund" with break-even of around 0.29 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Recs
louisfool
(65.21)
Submitted: 10/28/2011 3:32:42 PM :
Start Price:
$3.72
CRIS Score:
+36.07
Will underperform until approved. Look for a big pop once that happens.
Recs
Lcrazylegs84
(24.74)
Submitted: 9/17/2011 6:26:12 PM :
Start Price:
$3.17
CRIS Score:
-29.80
Its on a up hill battle..
Recs
waderjw
(55.72)
Submitted: 7/14/2011 10:54:21 AM :
Start Price:
$3.90
CRIS Score:
-37.02
They're having good trial runs on their cancer drugs.
Recs
EclecticRecluse
(77.97)
Submitted: 5/4/2011 4:50:35 AM :
Start Price:
$3.72
CRIS Score:
+29.35
High Price with Low Professional Opinion
Recs
thundiyi
(< 20)
Submitted: 2/4/2011 11:32:43 AM :
Start Price:
$2.94
CRIS Score:
-9.72
This stock has huge potential on the upside ($40 per share), and relatively low risk on the downside ($.75). They have financial support from large succesful organizations such as genetech and they have many avenues and ways to attempt to end various forms of cancer. This is currently the best attempt we have at ending certain types of cancer.
Recs
johnandmarie123
(< 20)
Submitted: 1/26/2011 1:12:49 PM :
Start Price:
$2.97
CRIS Score:
-11.65
has been noticed by the market as a potential takeover by big pharma
Recs
tttchicattt
(94.25)
Submitted: 9/8/2010 2:21:34 AM :
Start Price:
$1.27
CRIS Score:
+118.15
tmfbravobevo
Recs
jimmy8756309
(78.50)
Submitted: 8/31/2010 2:11:00 AM :
Start Price:
$1.24
CRIS Score:
+117.60
at 52 week low
Recs
Recs
runneil
(23.52)
Submitted: 7/13/2010 7:29:22 AM :
Start Price:
$1.50
CRIS Score:
+76.25
tough stock to own without the market winds at your back. a double is likley as good news on hedgehog still likely but any more bad news and....poof!
Recs
Recs
tunnel99
(< 20)
Submitted: 5/21/2010 12:58:26 PM :
Start Price:
$3.31
CRIS Score:
-48.46
This is going to be an outstanding stock for long term investor...More institutions investors invest in this small cap company.. Next year is going to be a great year!
Recs
Recs
popsie100
(< 20)
Submitted: 2/15/2010 2:10:49 PM :
Start Price:
$2.52
CRIS Score:
-15.62
The bright prospects Curis (CRIS) has have been ignored by the major movers on Wall Street. CRIS has 3 drugs in Phase 3 trials. In two of those trials they are partnering with Genetech, which is running the trials (and is now owned by Roche). One of these trials is a 100 person pivotal trial to show the long term effectiveness of their drug designed to cure basal cell carcinoma (BCC). This same drug had a very high overall response rate in a smaller Phase 2 BCC trial . Right now this same compound is being tested in many Phase 2 trials (to trest other cancers) sponsored by the National Cancer Institute and other prestigious health providers. I am a owner of CRIS.
Recs
crapsshooter
(84.88)
Submitted: 12/18/2009 2:24:56 PM :
Start Price:
$2.85
CRIS Score:
-29.82
No real reason just like the way this company looks.
Recs
Stonesolidpicks
(< 20)
Submitted: 12/4/2009 5:53:37 PM :
Start Price:
$2.91
CRIS Score:
-30.88
Many drugs in Phase 2
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 28 : 1 2 Next »